Lineage Cell Therapeutics FY2029 EPS Cut by B. Riley

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) - Investment analysts at B. Riley reduced their FY2029 earnings per share (EPS) estimates for Lineage Cell Therapeutics in a report released on Friday, May 23rd. B. Riley analyst M. Mamtani now anticipates that the company will earn $0.16 per share for the year, down from their previous forecast of $0.20. B. Riley currently has a "Buy" rating and a $3.00 target price on the stock. The consensus estimate for Lineage Cell Therapeutics' current full-year earnings is ($0.12) per share.

A number of other analysts have also recently issued reports on LCTX. D. Boral Capital reaffirmed a "buy" rating and issued a $2.00 price objective on shares of Lineage Cell Therapeutics in a research report on Tuesday, March 11th. HC Wainwright reaffirmed a "buy" rating and set a $9.00 price target on shares of Lineage Cell Therapeutics in a report on Tuesday, March 11th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, Lineage Cell Therapeutics currently has a consensus rating of "Buy" and an average target price of $4.20.

Lineage Cell Therapeutics Price Performance

NYSEAMERICAN LCTX traded down $0.04 on Monday, hitting $0.65. 190,536 shares of the stock were exchanged, compared to its average volume of 1,298,052. The company has a market capitalization of $142.17 million, a PE ratio of -5.38 and a beta of 1.21. The business's fifty day moving average is $0.48 and its 200 day moving average is $0.62. Lineage Cell Therapeutics has a 52 week low of $0.37 and a 52 week high of $1.15.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. increased its holdings in Lineage Cell Therapeutics by 13.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 677,162 shares of the company's stock worth $613,000 after purchasing an additional 82,864 shares in the last quarter. SG Americas Securities LLC grew its holdings in shares of Lineage Cell Therapeutics by 35.5% during the fourth quarter. SG Americas Securities LLC now owns 68,973 shares of the company's stock worth $35,000 after purchasing an additional 18,053 shares during the last quarter. Defender Capital LLC. increased its stake in shares of Lineage Cell Therapeutics by 19.2% in the fourth quarter. Defender Capital LLC. now owns 5,963,348 shares of the company's stock valued at $2,997,000 after buying an additional 961,150 shares during the period. Atria Wealth Solutions Inc. acquired a new position in shares of Lineage Cell Therapeutics in the fourth quarter valued at approximately $29,000. Finally, Red Crane Wealth Management LLC bought a new position in Lineage Cell Therapeutics in the 4th quarter valued at approximately $171,000. Institutional investors own 62.47% of the company's stock.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.